The ribosome is a complex biological machine that plays a central role in all living things and one that, according to Venki Ramakrishnan, could provide the key to combating the global scourge of antibiotic resistance. More…
LMB In The News
Behind the picture: a tiny cell-killing drill
Christos Savva, Electron Microscopy Facility scientist at the LMB, talks about why understanding structures of important proteins could be the key to treating many different diseases. More…
Vital nutrient has key role in keeping body clocks running on time
Magnesium – a nutrient found in many foods – helps control how cells keep their own form of time to cope with the natural environmental cycle of day and night, scientists in John O’Neill’s group at the LMB, and at the University of Edinburgh have found. More…
Allergan signs $3.3bn deal with Heptares
Heptares Therapeutics, an LMB spin-out company, announces a deal with Allergan for development of novel treatments for neurological disorders, including Alzheimer’s disease. More…
Artificial DNA could build new generation of cancer drugs
Scientists have built the first 3D nano-sized objects using artificial DNA, which could be used to deploy cancer treatments inside tumour cells. The teams from the LMB and The Institute of Cancer Research, London created microscopic pyramid- and diamond-shaped 3D ‘packets’ by folding together artificial nucleic acid building blocks called Xeno nucleic acids (XNAs). More…
Cambridge Pharmaceutical Cryo-EM Consortium
Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, LMB and the University of Cambridge. Sample preparation and data collection services on a cryo-transmission electron microscope (cryo-EM) will be provided to the consortium companies for early-stage drug discovery research. More…